The findings reveal a systemic proteostasis failure in aging brains, opening new therapeutic targets for age‑related cognitive impairment beyond traditional neurodegenerative markers.
The aging brain has long been associated with the buildup of a few notorious protein aggregates, such as amyloid‑β and tau, that drive neurodegenerative disease. Recent work from a leading neuroscience laboratory, however, demonstrates that protein aggregation is far more pervasive. By engineering a tagging system to label newly synthesized neuronal proteins, the researchers tracked protein turnover across the mouse lifespan. Their data show that average neuronal protein half‑life nearly doubles from early adulthood to old age, and they cataloged an "aggregome" comprising 1,726 proteins, many of which were previously unrelated to neurodegeneration.
A striking aspect of the study is the enrichment of synaptic proteins within the aggregome. Synaptic components are essential for neuronal communication, and their impaired turnover can destabilize synaptic architecture. The authors observed that 54% of the aggregated proteins also accumulate in microglia, the brain's resident immune cells, hinting at a compensatory clearance mechanism that may involve microglial pruning of compromised synapses. This cascade—from slowed proteome maintenance to synaptic protein aggregation and microglial engagement—offers a mechanistic bridge linking molecular aging to the functional decline observed in cognition and memory.
The broader implications extend to drug development and biomarker discovery. Targeting the cellular machinery that regulates protein half‑life, such as the ubiquitin‑proteasome system or autophagy pathways, could restore proteostasis and preserve synaptic integrity. Moreover, the aggregome signature may serve as an early indicator of brain aging before overt neurodegenerative pathology emerges. As the global population ages, understanding and intervening in this generalized protein aggregation process could become a cornerstone of strategies aimed at mitigating age‑related cognitive decline.
Comments
Want to join the conversation?
Loading comments...